Published in J Neurosci on May 25, 2011
Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp Neurol (2011) 1.27
Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling. Pharmacol Rev (2012) 1.21
Computational quest for understanding the role of astrocyte signaling in synaptic transmission and plasticity. Front Comput Neurosci (2012) 0.94
GABA release by hippocampal astrocytes. Front Comput Neurosci (2012) 0.93
α7 Nicotinic receptor-mediated astrocytic gliotransmitter release: Aβ effects in a preclinical Alzheimer's mouse model. PLoS One (2013) 0.91
Astrocytes conspire with neurons during progression of neurological disease. Curr Opin Neurobiol (2012) 0.90
Astrocytic GABA transporter GAT-1 dysfunction in experimental absence seizures. J Physiol (2012) 0.89
Gq-DREADD Selectively Initiates Glial Glutamate Release and Inhibits Cue-induced Cocaine Seeking. Biol Psychiatry (2015) 0.88
Long-lasting LTP requires neither repeated trains for its induction nor protein synthesis for its development. PLoS One (2012) 0.88
Glutamatergic input-output properties of thalamic astrocytes. Neuroscience (2012) 0.87
Characterization of Panglial Gap Junction Networks in the Thalamus, Neocortex, and Hippocampus Reveals a Unique Population of Glial Cells. Cereb Cortex (2014) 0.85
Astrocytic adenosine: from synapses to psychiatric disorders. Philos Trans R Soc Lond B Biol Sci (2014) 0.85
Heterogeneity in expression of functional ionotropic glutamate and GABA receptors in astrocytes across brain regions: insights from the thalamus. Philos Trans R Soc Lond B Biol Sci (2014) 0.84
Novel astrocyte targets: new avenues for the therapeutic treatment of epilepsy. Neuroscientist (2014) 0.83
Astroglial calcium signaling displays short-term plasticity and adjusts synaptic efficacy. Front Cell Neurosci (2015) 0.82
Persistent receptor activity underlies group I mGluR-mediated cellular plasticity in CA3 neuron. J Neurosci (2013) 0.81
Research tool: Validation of floxed α7 nicotinic acetylcholine receptor conditional knockout mice using in vitro and in vivo approaches. J Physiol (2014) 0.80
Monitoring Astrocytic Proteome Dynamics by Cell Type-Specific Protein Labeling. PLoS One (2015) 0.80
GABA(B) receptor-mediated activation of astrocytes by gamma-hydroxybutyric acid. Philos Trans R Soc Lond B Biol Sci (2014) 0.78
Modulation of Synaptic Plasticity by Glutamatergic Gliotransmission: A Modeling Study. Neural Plast (2016) 0.77
Behavioral assessment of acute inhibition of system xc (-) in rats. Psychopharmacology (Berl) (2014) 0.77
Astrocytic Actions on Extrasynaptic Neuronal Currents. Front Cell Neurosci (2015) 0.77
Pituitary Adenylate cyclase-activating polypeptide orchestrates neuronal regulation of the astrocytic glutamate-releasing mechanism system xc (.). J Neurochem (2016) 0.76
Arsenic exposure and glutamate-induced gliotransmitter release from astrocytes. Neural Regen Res (2012) 0.76
Computational simulation: astrocyte-induced depolarization of neighboring neurons mediates synchronous UP states in a neural network. J Biol Phys (2015) 0.75
Astrocyte and Neuronal Plasticity in the Somatosensory System. Neural Plast (2015) 0.75
Astrocyte-Dependent Slow Inward Currents (SICs) Participate in Neuromodulatory Mechanisms in the Pedunculopontine Nucleus (PPN). Front Cell Neurosci (2017) 0.75
Behavioral improvement and regulation of molecules related to neuroplasticity in ischemic rat spinal cord treated with PEDF. Neural Plast (2014) 0.75
Orofacial Neuropathic Pain Leads to a Hyporesponsive Barrel Cortex with Enhanced Structural Synaptic Plasticity. PLoS One (2016) 0.75
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci (2002) 7.57
NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol (2001) 6.96
Astrocytic purinergic signaling coordinates synaptic networks. Science (2005) 6.55
Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling. Science (1990) 6.02
Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci (2005) 5.97
Grouping of brain rhythms in corticothalamic systems. Neuroscience (2005) 5.21
Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci (1999) 5.02
Electrophysiological properties of guinea-pig thalamic neurones: an in vitro study. J Physiol (1984) 4.98
Tuned responses of astrocytes and their influence on hemodynamic signals in the visual cortex. Science (2008) 4.82
Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell (2006) 4.53
Glutamate exocytosis from astrocytes controls synaptic strength. Nat Neurosci (2007) 4.43
Long-term potentiation depends on release of D-serine from astrocytes. Nature (2010) 4.36
Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron (2004) 4.35
Astrocytic Ca2+ signaling evoked by sensory stimulation in vivo. Nat Neurosci (2006) 4.23
Astrocyte-mediated potentiation of inhibitory synaptic transmission. Nat Neurosci (1998) 4.20
Hippocampal short- and long-term plasticity are not modulated by astrocyte Ca2+ signaling. Science (2010) 3.77
On the actions that one nerve cell can have on another: distinguishing "drivers" from "modulators". Proc Natl Acad Sci U S A (1998) 3.70
An astrocytic basis of epilepsy. Nat Med (2005) 3.50
Spontaneous astrocytic Ca2+ oscillations in situ drive NMDAR-mediated neuronal excitation. Nat Neurosci (2001) 3.21
Quantal analysis of synaptic potentials in neurons of the central nervous system. Physiol Rev (1990) 3.19
Intracellular calcium oscillations in astrocytes: a highly plastic, bidirectional form of communication between neurons and astrocytes in situ. J Neurosci (1997) 3.18
Do astrocytes really exocytose neurotransmitters? Nat Rev Neurosci (2010) 3.17
Selective stimulation of astrocyte calcium in situ does not affect neuronal excitatory synaptic activity. Neuron (2007) 3.15
Hippocampal astrocytes in situ respond to glutamate released from synaptic terminals. J Neurosci (1996) 2.90
Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nat Neurosci (2004) 2.89
Tonic and burst firing: dual modes of thalamocortical relay. Trends Neurosci (2001) 2.89
Control of glutamate clearance and synaptic efficacy by glial coverage of neurons. Science (2001) 2.85
Astrocytes potentiate transmitter release at single hippocampal synapses. Science (2007) 2.81
NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci (1993) 2.76
The slow (<1 Hz) rhythm of non-REM sleep: a dialogue between three cardinal oscillators. Nat Neurosci (2009) 2.51
Channel-mediated tonic GABA release from glia. Science (2010) 2.42
Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron (2010) 2.36
Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc Natl Acad Sci U S A (2003) 2.35
Glutamate released from glial cells synchronizes neuronal activity in the hippocampus. J Neurosci (2004) 2.32
Properties of synaptically evoked astrocyte calcium signal reveal synaptic information processing by astrocytes. J Neurosci (2005) 2.16
Loss of IP3 receptor-dependent Ca2+ increases in hippocampal astrocytes does not affect baseline CA1 pyramidal neuron synaptic activity. J Neurosci (2008) 2.14
Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J Neurosci (2004) 2.11
Cellular mechanisms of the slow (<1 Hz) oscillation in thalamocortical neurons in vitro. Neuron (2002) 2.04
GABAergic network activation of glial cells underlies hippocampal heterosynaptic depression. J Neurosci (2006) 1.93
SNARE protein-dependent glutamate release from astrocytes. J Neurosci (2000) 1.86
Astrocytic control of synaptic NMDA receptors. J Physiol (2007) 1.85
mGluR5 stimulates gliotransmission in the nucleus accumbens. Proc Natl Acad Sci U S A (2007) 1.77
Intracellular astrocyte calcium waves in situ increase the frequency of spontaneous AMPA receptor currents in CA1 pyramidal neurons. J Neurosci (2004) 1.76
NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. J Neurosci (2006) 1.69
Long-term modulation of electrical synapses in the mammalian thalamus. Science (2005) 1.55
Synaptically released acetylcholine evokes Ca2+ elevations in astrocytes in hippocampal slices. J Neurosci (2002) 1.52
Sensory and cortical activation of distinct glial cell subtypes in the somatosensory thalamus of young rats. Eur J Neurosci (2010) 1.51
Developmental profile and properties of sulforhodamine 101--Labeled glial cells in acute brain slices of rat hippocampus. J Neurosci Methods (2007) 1.47
Distinct NMDA receptor subpopulations contribute to long-term potentiation and long-term depression induction. J Neurosci (2000) 1.38
Astrocytic glutamate is not necessary for the generation of epileptiform neuronal activity in hippocampal slices. J Neurosci (2006) 1.36
An excitatory loop with astrocytes contributes to drive neurons to seizure threshold. PLoS Biol (2010) 1.35
The relay of high-frequency sensory signals in the Whisker-to-barreloid pathway. J Neurosci (2003) 1.34
Anion channels in astrocytes: biophysics, pharmacology, and function. Glia (2006) 1.32
Synchronous neural activity and memory formation. Curr Opin Neurobiol (2010) 1.32
Purinergic receptors mediate two distinct glutamate release pathways in hippocampal astrocytes. J Biol Chem (2005) 1.21
The role of Ca2+ in the generation of spontaneous astrocytic Ca2+ oscillations. Neuroscience (2003) 1.15
Developmental remodelling of the lemniscal synapse in the ventral basal thalamus of the mouse. J Physiol (2006) 1.15
Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J Neurochem (1999) 1.13
Glutamate-mediated astrocyte-to-neuron signalling in the rat dorsal horn. J Physiol (2010) 1.12
Developmental synaptic plasticity at the thalamocortical input to barrel cortex: mechanisms and roles. Mol Cell Neurosci (2007) 1.06
Pacemaker calcium oscillations in thalamic astrocytes in situ. Neuroreport (2001) 1.06
Astrocyte activation of presynaptic metabotropic glutamate receptors modulates hippocampal inhibitory synaptic transmission. Neuron Glia Biol (2004) 1.03
ATP-dependent infra-slow (<0.1 Hz) oscillations in thalamic networks. PLoS One (2009) 1.02
Progression of change in NMDA, non-NMDA, and metabotropic glutamate receptor function at the developing corticothalamic synapse. J Neurophysiol (1998) 0.99
Novel modes of rhythmic burst firing at cognitively-relevant frequencies in thalamocortical neurons. Brain Res (2008) 0.92
Ontogenetic changes in the projections of neocortical neurons. J Neurosci (1982) 0.86
Astrocytes, spontaneity, and the developing thalamus. J Physiol Paris (2002) 0.82
Neuronal maturation and synaptogenesis in the rat ventrobasal complex: alignment with developmental changes in rate and severity of axon reaction. J Comp Neurol (1977) 0.80
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
Synchronized oscillations at alpha and theta frequencies in the lateral geniculate nucleus. Neuron (2004) 1.92
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52
Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
GLM-beamformer method demonstrates stationary field, alpha ERD and gamma ERS co-localisation with fMRI BOLD response in visual cortex. Neuroimage (2005) 1.35
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos (2006) 1.27
Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos (2006) 1.26
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer (2008) 1.18
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.18
Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest (2006) 1.13
The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther (2003) 1.13
Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol (2003) 1.11
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11
Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med (2007) 1.08
Association between the CYP3A5 genotype and blood pressure. Hypertension (2004) 1.07
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos (2002) 1.06
Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther (2007) 1.04
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther (2006) 1.02
The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos (2002) 1.01
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99
Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos (2009) 0.99
The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS (2008) 0.99
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99
Rapid aquaporin translocation regulates cellular water flow: mechanism of hypotonicity-induced subcellular localization of aquaporin 1 water channel. J Biol Chem (2012) 0.97
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos (2004) 0.96
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96
Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol (2006) 0.95
Literature mining on pharmacokinetics numerical data: a feasibility study. J Biomed Inform (2009) 0.93
In vivo real-time 3-D intracardiac echo using PMUT arrays. IEEE Trans Ultrason Ferroelectr Freq Control (2014) 0.92
Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos (2008) 0.91
α7 Nicotinic receptor-mediated astrocytic gliotransmitter release: Aβ effects in a preclinical Alzheimer's mouse model. PLoS One (2013) 0.91
A general linear model for MEG beamformer imaging. Neuroimage (2004) 0.91
Infraslow (<0.1 Hz) oscillations in thalamic relay nuclei basic mechanisms and significance to health and disease states. Prog Brain Res (2011) 0.90
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg (2013) 0.90
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos (2012) 0.89
Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest (2007) 0.89
Astrocytic GABA transporter GAT-1 dysfunction in experimental absence seizures. J Physiol (2012) 0.89
Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol (2012) 0.88
Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos (2002) 0.88
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos (2005) 0.88
Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol (2005) 0.88
Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology (2005) 0.87
The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol (2002) 0.87
A new probabilistic rule for drug-dug interaction prediction. J Pharmacokinet Pharmacodyn (2009) 0.86
Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution. J Chem Inf Model (2013) 0.86
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos (2005) 0.85
Oscillatory beta activity mediates neuroplastic effects of motor cortex stimulation in humans. J Neurosci (2013) 0.85
Airflow and droplet spreading around oxygen masks: a simulation model for infection control research. Am J Infect Control (2007) 0.85
NT2 derived neuronal and astrocytic network signalling. PLoS One (2012) 0.84
Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Ther Drug Monit (2008) 0.84
Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. J Alzheimers Dis (2012) 0.83
Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest (2009) 0.83
Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol (2005) 0.83
Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol (2007) 0.83
Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos (2013) 0.82
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol (2012) 0.82
Primary and secondary somatosensory cortex responses to anticipation and pain: a magnetoencephalography study. Eur J Neurosci (2011) 0.82
Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther (2008) 0.82
A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. Proteomics (2008) 0.82
A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) models. J Biopharm Stat (2009) 0.81
The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metab Dispos (2004) 0.81
Irreversible enzyme inhibition kinetics and drug-drug interactions. Methods Mol Biol (2014) 0.81
The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine. Drug Metab Dispos (2013) 0.81
Novel neuronal and astrocytic mechanisms in thalamocortical loop dynamics. Philos Trans R Soc Lond B Biol Sci (2002) 0.81
CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos (2013) 0.80
A multimodal perspective on the composition of cortical oscillations. Front Hum Neurosci (2013) 0.80
Functional astrocyte-neuron lactate shuttle in a human stem cell-derived neuronal network. J Cereb Blood Flow Metab (2013) 0.80
Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats. Drug Metab Dispos (2010) 0.79
Astrocyte plasticity: implications for synaptic and neuronal activity. Neuroscientist (2013) 0.79
Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos (2012) 0.78
Gamma-hydroxybutyrate does not maintain self-administration but induces conditioned place preference when injected in the ventral tegmental area. Int J Neuropsychopharmacol (2009) 0.78
A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.78
Drug-drug interaction prediction assessment. J Biopharm Stat (2009) 0.77
Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Dispos (2008) 0.77
Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos (2011) 0.76
Live volumetric imaging (LVI) intracardiac ultrasound catheter. Cardiovasc Revasc Med (2013) 0.76
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177. J Acquir Immune Defic Syndr (2010) 0.76
The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. Drug Metab Dispos (2012) 0.75
QT effect of semagacestat at therapeutic and supratherapeutic doses. Int J Clin Pharmacol Ther (2012) 0.75